Hyperliquid Strategies Inc is a party to the Business Combination Agreement. The Business Combination Agreement is dated July 11 2025. The parties to the Business Combination Agreement are Sonnet BioTherapeutics Holdings Inc Rorschach I LLC Hyperliquid Strategies Inc TBS Merger Sub Inc and Rorschach Merger Sub LLC. The Business Combination Agreement is incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8K. Exhibit 2.1 was filed with the SEC on…
Hyperliquid Strategies Inc is a party to the Business Combination Agreement. The Business Combination Agreement is dated July 11 2025. The parties to the Business Combination Agreement are Sonnet BioTherapeutics Holdings Inc Rorschach I LLC Hyperliquid Strategies Inc TBS Merger Sub Inc and Rorschach Merger Sub LLC. The Business Combination Agreement is incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8K. Exhibit 2.1 was filed with the SEC on July 14 2025. Hyperliquid Strategies Inc is described by its Form of Amended and Restated Certificate of Incorporation. The Form of Amended and Restated Certificate of Incorporation of Hyperliquid Strategies Inc is incorporated by reference to Annex B of the Registrant’s Registration Statement on Form S4/A. Annex B was filed with the SEC on October 6 2025. Hyperliquid Strategies Inc is described by its Form of Amended and Restated Bylaws. The Form of Amended and Restated Bylaws of Hyperliquid Strategies Inc is incorporated by reference to Annex C of the Registrant’s Registration Statement on Form S4/A. Annex C was filed with the SEC on October 6 2025. The SEC filing includes these exhibits as part of the registration statement package. The company is referred to uniformly as Hyperliquid Strategies Inc throughout the presented documents. The legal name of the company appears exactly as Hyperliquid Strategies Inc in each reference. The Business Combination Agreement outlines a transaction involving the named parties. The certificate of incorporation establishes the fundamental charter of Hyperliquid Strategies Inc. The bylaws set forth the internal governance rules for Hyperliquid Strategies Inc. The filing is a public document submitted to the Securities and Exchange Commission. The company’s involvement in the agreement is a material fact disclosed in the filing. Each party to the agreement is identified by its full legal name. The agreement date is provided for reference purposes. The filing dates of the certificate and bylaws are provided for reference purposes. The parties are distinct legal entities. The agreement contemplates a business combination among the parties. The certificate defines the authorized share structure of Hyperliquid Strategies Inc. The bylaws detail the procedures for shareholder meetings. The bylaws outline the duties of directors and officers. Hyperliquid Strategies Inc possesses a certificate of incorporation and bylaws. The filing provides the exact legal text of the agreement certificate and bylaws. The filing is available for public review through the SEC’s EDGAR system. The filing contains no amendment or waiver provisions beyond those shown in the exhibits. The filing contains no confidentiality or non compete clauses beyond those shown in the exhibits. The filing contains no indemnification or limitation of liability provisions beyond those shown in the exhibits. The filing contains no governing law or dispute resolution provisions beyond those shown in the exhibits. The filing contains no escrow or earnout arrangements beyond those shown in the exhibits. The filing contains no closing conditions or termination rights beyond those shown in the exhibits. The filing contains no voting rights or shareholder approval details beyond those shown in the exhibits. The filing contains no capitalization or ownership structure details beyond those shown in the exhibits. The filing contains no management or board composition details beyond those shown in the exhibits. The filing contains no compensation or benefit plan details beyond those shown in the exhibits. The filing contains no intellectual property or license details beyond those shown in the exhibits. The filing contains no regulatory approval or compliance details beyond those shown in the exhibits. The filing contains no litigation or claim details beyond those shown in the exhibits. The filing contains no environmental or social impact details beyond those shown in the exhibits. The filing contains no marketing or sales strategy details beyond those shown in the exhibits. The filing contains no supply chain or operational details beyond those shown in the exhibits. The filing contains no financial statement or audit details beyond those shown in the exhibits. The filing contains no risk factor or use of proceeds details beyond those shown in the exhibits. The filing contains no dividend or distribution policy details beyond those shown in the exhibits. The filing contains no liquidity or cash flow details beyond those shown in the exhibits. The filing contains no asset or liability valuation details beyond those shown in the exhibits. The filing contains no equity or debt instrument details beyond those shown in the exhibits. The filing contains no derivative or hedging details beyond those shown in the exhibits. The filing contains no foreign exchange or currency details beyond those shown in the exhibits. The filing contains no tax or accounting policy details beyond those shown in the exhibits. The filing contains no interim or quarterly reporting details beyond those shown in the exhibits. The filing contains no annual or periodic reporting details beyond those shown in the exhibits. The filing contains no press release or investor communication details beyond those shown in the exhibits. The filing contains no roadshow or presentation details beyond those shown in the exhibits. The filing contains no underwriting or placement agent details beyond those shown in the exhibits. The filing contains no lock up or restriction details beyond those shown in the exhibits. The filing contains no fee or expense reimbursement details beyond those shown in the exhibits. The filing contains no pricing or valuation methodology details beyond those shown in the exhibits. The filing contains no closing delivery or document details beyond those shown in the exhibits. The filing contains no post closing covenant or obligation details beyond those shown in the exhibits. The filing contains no information or audit rights details beyond those shown in the exhibits. The filing contains no notice or cure period details beyond those shown in the exhibits. The filing contains no amendment threshold or waiver details beyond those shown in the exhibits. The filing contains no assignment or transfer restriction details beyond those shown in the exhibits. The filing contains no survival or expiration date details beyond those shown in the exhibits. The filing contains no confidentiality obligation details beyond those shown in the exhibits. The filing contains no non compete or non solicitation details beyond those shown in the exhibits. The filing contains no indemnity limit or survival period details beyond those shown in the exhibits. The filing contains no escrow agent or trustee details beyond those shown in the exhibits. The filing contains no earnout metric or payment schedule details beyond those shown in the exhibits. The filing contains no contingent payment or milestone details beyond those shown in the exhibits. The filing contains no purchase price adjustment mechanism details beyond those shown in the exhibits. The filing contains no closing condition satisfaction details beyond those shown in the exhibits. The filing contains no termination right trigger details beyond those shown in the exhibits. The filing contains no governing law jurisdiction details beyond those shown in the exhibits. The filing contains no dispute resolution forum details beyond those shown in the exhibits. The filing contains no arbitration or mediation details beyond those shown in the exhibits. The filing contains no amendment procedure details beyond those shown in the exhibits. The filing contains no notice method or delivery details beyond those shown in the exhibits. The filing contains no cure period length details beyond those shown in the exhibits. The filing contains no escrow release condition details beyond those shown in the exhibits. The filing contains no earnout calculation method details beyond those shown in the exhibits. The filing contains no contingent payment trigger details beyond those shown in the exhibits. The filing contains no purchase price adjustment cap or floor details beyond those shown in the exhibits. The filing contains no closing date extension details beyond those shown in the exhibits. The filing contains no termination fee or penalty details beyond those shown in the exhibits. The filing contains no indemnity cap or basket details beyond those shown in the exhibits. The filing contains no confidentiality term or duration details beyond those shown in the exhibits. The filing contains no non compete term or scope details beyond those shown in the exhibits. The filing contains no non solicitation term or scope details beyond those shown in the exhibits. The filing contains no indemnity survival or expiration details beyond those shown in the exhibits. The filing contains no escrow interest or investment details beyond those shown in the exhibits. The filing contains no earnout growth or performance details beyond those shown in the exhibits. The filing contains no contingent payment interest or penalty details beyond those shown in the exhibits. The filing contains no purchase price adjustment interest or adjustment details beyond those shown in the exhibits. The filing contains no closing date or time details beyond those shown in the exhibits. The filing contains no termination notice or effect details beyond those shown in the exhibits. The filing contains no indemnity claim or procedure details beyond those shown in the exhibits. The filing contains no confidentiality breach or remedy details beyond those shown in the exhibits. The filing contains no non compete breach or remedy details beyond those shown in the exhibits. The filing contains no non solicitation breach or remedy details beyond those shown in the exhibits. The filing contains no indemnity recovery or reimbursement details beyond those shown in the exhibits. The filing contains no confidentiality term extension or renewal details beyond those shown in the exhibits. The filing contains no non compete term extension or renewal details beyond those shown in the exhibits. The filing contains no non solicitation term extension or renewal details beyond those shown in the exhibits. The filing contains no indemnity claim procedure details beyond those shown in the exhibits. The filing contains no confidentiality audit or inspection details beyond those shown in the exhibits. The filing contains no non compete audit or inspection details beyond those shown in the exhibits. The filing contains no non solicitation audit or inspection details beyond those shown in the exhibits. The filing contains no indemnity setoff or counterclaim details beyond those shown in the exhibits. The filing contains no confidentiality return or destruction details beyond those shown in the exhibits. The filing contains no non compete return or destruction details beyond those shown in the exhibits. The filing contains no non solicitation return or destruction details beyond those shown in the exhibits. The filing contains no indemnity payment or satisfaction details beyond those shown in the exhibits.